Tagged: Oncology

ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated with Alectinib: A Case Report

There are few reported cases of ALK gene rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC) during pregnancy. There is a lack of information on the safety of ALK inhibitors in pregnant patients. We present a 25-year-old African American woman who was diagnosed with metastatic ALK+ lung adenocarcinoma at 15 weeks of gestation. Treatment with alectinib was initiated at 18 weeks’ gestation with resultant radiological treatment response. The patient did not experience any adverse effects from alectinib during her pregnancy.